NAGE

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will present at the East Coast IDEAS Investor Conference on Thursday, June 11, 2026, at The Westin Times Square in New York, NY. IDEAS Conferences provide independent regional venues for quality companies to present their investment merits to influential audiences of investment professionals, offering investor-sponsored events designed to benefit regional investment communities. Niagen Bioscience CEO, Rob Fried, will present on Thursday, June 11, from 2:40 - 3:15 PM ET in the Presenting Room. The pres

The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the Niagen Research Program, reflecting the Company's name evolution with a focus on advancing the understanding and applications of NAD+ through its flagship ingredient, N

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate in the following upcoming conferences: 31st Annual Sohn Investment Conference Location: Jazz at Lincoln Center's Frederick P. Rose Hall Date: May 12, 2026 Format: Emerging Company Pavilion, a curated showcase of 8-10 select companies Management: Ozan Pamir, CFO 4th Annual Benchmark Consumer One-On-One Conference Location: New York Athletic Club Date: May 19, 2026 Format: One-on-one meetings Management: Rob Fried, CEO, and Ozan Pamir, CFO If you would like t

8-K - Niagen Bioscience, Inc. (0001386570) (Filer)

Net sales increased to $31.5 million Gross margin improved to 63.5% Net income of $6.3 million, up $1.3 million from the prior year and adjusted EBITDA of $3.8 million Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2026. First Quarter 2026 Financial Highlights Total net sales increased 3% to $31.5 million, including $22.4 million from Tru Niagen®. Excluding the recently sold Analytical Reference Standards and Services segment from both periods, net sales rose 5% to $31.1 million. Gross margin of 63.5%, reflecting continued strength in business mix. Net income of $6.3 million, including a $4.8 million gain on the divestiture

10-Q - Niagen Bioscience, Inc. (0001386570) (Filer)

New telehealth platform introduces prescription-only Niagen At-Home Injection Kit, expanding access to pharmaceutical-grade NAD+ support for cellular and tissue health delivered directly to eligible patients' doors Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of its clinician-directed telehealth platform under Niagen™ Plus, enabling eligible patients in the U.S. to access prescription-only, pharmaceutical-grade Niagen® (patented nicotinamide riboside chloride, NRCl) from home with the first-of-its-kind Niagen® At-Home Injection Kit. The launch marks Niagen Bi

DEFA14A - Niagen Bioscience, Inc. (0001386570) (Filer)

DEF 14A - Niagen Bioscience, Inc. (0001386570) (Filer)

Partnership unlocks Olympia's established clinic network for Niagen Plus, expands pharmaceutical-grade Niagen supply chain, and brings liquid compounded vials to market Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced a new partnership with Olympia Pharmaceuticals, a state-of-the-art U.S. FDA-registered 503B outsourcing facility, to compound and distribute pharmaceutical-grade Niagen® (patented nicotinamide riboside, NR) for the Company's Niagen Plus™ intravenous and injectable products. Olympia Pharmaceuticals joins Wells Pharma of Houston, diversifying the Company's 503B

4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Wednesday, May 6, 2026, at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2026. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, May 6, 2026. Investor Conference Call: A live webcast will be held on Wednesday, May 6, 2026, at 4:30 p.m. Eastern Daylight Time (1:30 p.m. Pacific Daylight Time) to discuss Niagen Bioscience's first quarter financial results and provide a

NR is the first among NR, NMN, and NAD+ to receive a pharmacopeial quality benchmark, reinforcing Niagen Bioscience's leadership in NAD+ science and ingredient quality Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that Nicotinamide Riboside Chloride (NRCl), the patented form of nicotinamide riboside in the Company's flagship ingredient, Niagen®, now has a published United States Pharmacopeia (USP) dietary supplement ingredient monograph. This monograph reflects the scientific rigor behind Niagen and establishes a global benchmark for what high-quality NRCl should look li

Niagen IV launches across Medi-Spa clinics on high-end cruise ships, expanding Niagen Plus' footprint Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced OneSpaWorld (NASDAQ:OSW) as the newest Niagen Plus™ provider, engaged to offer pharmaceutical grade Niagen IV at over 80 Medi-Spa clinics onboard high-end cruise ships. Marking Niagen Bioscience's first cruise ship clinic partnership, this collaboration brings Niagen IV to guests at sea. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331977078/en/Niagen IV laun

8-K - Niagen Bioscience, Inc. (0001386570) (Filer)

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has authorized an increase to the Company's previously disclosed share repurchase program (the "Program"), raising the total authorization from $10 million to $20 million of the Company's outstanding common stock. Through March 17, 2026, the Company has repurchased approximately $2.6 million of its common stock under the Share Repurchase Program. Additional information regarding share repurchases will be reported in the Company's periodic reports filed with the SEC. Rob Fried, CEO, Niagen Bioscie

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the 38th Annual ROTH Conference, taking place at The Ritz-Carlton Laguna Niguel in Dana Point, California, from March 22 to 24, 2026. Niagen Bioscience CEO, Rob Fried, will participate in the Technologies Advancing Healthy Aging Panel on Monday, March 23, at 2:00 PM PT (5:00 PM ET). The panel will be livestreamed and available at www.event.summitcast.com. Additionally, Niagen Bioscience's CEO, Rob Fried, and CFO, Ozan Pamir, will attend one-on-one meetings with institutional investor

By supporting investigator-initiated research worldwide, the program has helped establish Niagen Bioscience as a foundational force in advancing NAD+ understanding across the industry Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its external research program has surpassed 300 material transfer agreements (MTAs) with investigators and research institutions around the world, marking a major milestone for what the Company believes is the most extensive dedicated NAD+ research support program in the world. Rob Fried, CEO, Niagen Bioscience, commented, "Reaching more

8-K - Niagen Bioscience, Inc. (0001386570) (Filer)

Net sales increased 30% year-over-year to $129.4 million in 2025 Gross margin increased 250 bps year-over-year to 64.3% in 2025 Net income increased 103% year-over-year to $17.4 million in 2025 Adjusted EBITDA increased 139% year-over-year to $20.4 million in 2025 Cash and cash equivalents totaled $64.8 million at December 31, 2025 compared to $44.7 million at December 31, 2024 Full year 2026 net sales outlook reflects between 10-15% growth, excluding the recently sold reference standards segment Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced its fourth quarter and fiscal year 2025 financial results. Fourth Quarter 2025 Financial Highlights Compared to Prior Year Quarter Total

10-K - Niagen Bioscience, Inc. (0001386570) (Filer)

Next-generation cellular therapies and regenerative medicine drive exponential expansionNEW YORK, March 3, 2026 /CNW/ -- Market News Updates News Commentary - The global anti-aging therapy market is gaining serious momentum as people live longer and actively look for ways to stay healthier, more energetic, and more youthful. What was once considered a niche cosmetic category has evolved into a major healthcare and biotech opportunity. Industry forecasts project the broader anti-aging market could surpass $420 billion by 2030, growing at an estimated 8–9% compound annual growth rate (CAGR). This growth is being fueled by rising healthcare awareness, advances in biotechnology, and increased de

8-K - Niagen Bioscience, Inc. (0001386570) (Filer)

Divestiture streamlines operations and advances the Company's strategy to fully exit non-core activities Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the sale of its ChromaDex Reference Standards business to LGC, as of February 24, 2026, in an all-cash transaction. The divestiture further streamlines Niagen Bioscience's operations, advances the Company's strategy to exit non-core activities, and focuses resources on NAD+ science, intellectual property, and commercial growth within the longevity industry. Rob Fried, CEO of Niagen Bioscience, remarked, "This transaction

Patent strengthens Niagen Bioscience's intellectual property moat in fast-growing NAD+-boosting IV and injectable delivery formats, supporting commercial expansion and deterring infringers Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the broadening of its NAD+ precursor intellectual property (IP) portfolio with the newly granted U.S. Patent No. 12,558,367, which covers the methods of use of nicotinamide riboside (NR) and derivatives in intravenous and injectable formulations. Rob Fried, CEO of Niagen Bioscience, commented, "This patent expands our intellectual propert